Document is current
Any future updates will be listed below
-
Authors
Nielly, Hubert https://orcid.org/0000-0002-8042-5716
Bialé, L. https://orcid.org/0000-0001-8496-4330
Gilardin, L. https://orcid.org/0000-0001-9212-0859
Carmoi, T. https://orcid.org/0000-0001-6787-718X
Éon, A.
Vanquaethem, H. https://orcid.org/0000-0002-8262-9085
Fougerousse, A-C https://orcid.org/0000-0002-2850-867X
- License Information
-
More Information
Article History
Received: 13 April 2024
Accepted: 5 July 2024
First Online: 16 July 2024
Declarations
:
: Ethical approval for this case was obtained from IRB 00013918 direction de la formation, de la recherche et de l’innovation* – DFRI IRB #1 (IORG0011755). Written informed consent was obtained for anonymized patient information to be published in this article, including the publication of the pictures.
: none (A-C Fougerousse has received consulting fees, lecture honoraria and support for attending meeting, and has participated on data safety monitoring board for Abbvie, Janssen, Leo Pharma, Lilly, Novartis, UCB Pharma and Almirall, not relied to the present publication).
